Evidence map›Paper›PMID 31581069›Full record

ArticleRedox biology2020

DNA damage and synaptic and behavioural disorders in glucose-6-phosphate dehydrogenase-deficient mice.

Margaret M Loniewska, Anmol Gupta, Shama Bhatia, Isabel MacKay-Clackett, Zhengping Jia, Peter G Wells

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Margaret M LoniewskaFaculty of Pharmacy and Centre for Pharmaceutical Oncology, University of Toronto, Toronto, Ontario, Canada.
Anmol GuptaDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Shama BhatiaFaculty of Pharmacy and Centre for Pharmaceutical Oncology, University of Toronto, Toronto, Ontario, Canada.
Isabel MacKay-ClackettDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Zhengping JiaNeurosciences and Mental Health, The Hospital for Sick Children, Toronto, and Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
Peter G WellsFaculty of Pharmacy and Centre for Pharmaceutical Oncology, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Electronic address: pg.wells@utoronto.ca.
University of Toronto · CASickKids Foundation · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mice deficient in glucose-6-phosphate dehydrogenase (G6PD) cannot replenish the cellular antioxidant glutathione, which detoxifies neurodegenerative reactive oxygen species (ROS). To determine the functional consequences of G6PD deficiency, young and aging G6PD-deficient mice were evaluated for brain G6PD activity, DNA damage (comets, γH2AX), Purkinje cell loss, brain function (electrophysiology, behaviour) and lifespan. DNA comet formation was increased and Purkinje cell counts were decreased in a G6pd gene dose-dependent fashion. γH2AX formation varied by age, sex and brain region, with increased levels in G6PD-deficient young and aging females, and in aging males. Aging male G6PD-deficient mice exhibited synaptic dysfunction in hippocampal slices. G6PD-deficient young and aging females exhibited deficits in executive function, and young deficient mice exhibited deficits in social dominance. Conversely, median lifespan in G6PD-deficient females and males was enhanced. Enhanced ROS-initiated brain damage in G6PD deficiency has functional consequences, suggesting that G6PD protects against ROS-mediated neurodegenerative disorders.

Indexed as

DNA DamageAnimalsBrainDisease Models, AnimalDNA Breaks, Double-StrandedDNA Breaks, Single-StrandedEnzyme ActivationFemaleGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyMaleMental DisordersMiceOxidation-ReductionPurkinje CellsGlucosephosphate Dehydrogenase8-Oxo-2′-deoxyguanine (8-oxodG)AgingBehavioural disordersCometDNA damageElectrophysiologyGamma-H2AX (γH2AX)Glucose-6-phosphate dehydrogenase (G6PD)LifespanNeurodegenerationReactive oxygen species (ROS)

Identifiers

PMID31581069
PMCPMC6812046
OpenAlexW2974698016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.